Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Idiopathic Thrombocytopenic Purpura Clinical Trials
Idiopathic Thrombocytopenic Purpura clinical trials are recruiting across 42 cities. Here are the cities with the most active studies:
Idiopathic Thrombocytopenic Purpura Trial Phases
10 research organizations are sponsoring idiopathic thrombocytopenic purpura trials.
About Idiopathic Thrombocytopenic Purpura
Immune thrombocytopenia (ITP) is an autoimmune condition where the immune system destroys platelets, leading to easy bruising and bleeding. It can occur in children (often self-limiting) or adults (often chronic). Treatment includes corticosteroids, thrombopoietin receptor agonists, and rituximab.
Clinical trials are advancing new treatments for idiopathic thrombocytopenic purpura. Currently, 11 studies are recruiting a combined 999 participants across the United States. Research is being conducted by 10 organizations including Takeda, Novartis Pharmaceuticals, Massachusetts General Hospital and 7 others.
2026 Idiopathic Thrombocytopenic Purpura Research Landscape
As of July 2026, the idiopathic thrombocytopenic purpura clinical trial landscape includes 11 actively recruiting studies across 42 cities in the United States. These studies are collectively seeking 999 participants, with an average enrollment target of 91 per study.
The research spans multiple phases of development: 5 studies are in PHASE3, 5 studies are in PHASE2, 1 study is in PHASE1. The presence of Phase 3 trials indicates that some idiopathic thrombocytopenic purpura treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 10 different organizations, including Takeda, Novartis Pharmaceuticals, Massachusetts General Hospital, Pfizer, argenx, and 5 others.
Geographically, idiopathic thrombocytopenic purpura trials are most concentrated in Los Angeles, California (7 trials); Boston, Massachusetts (5 trials); Washington D.C., District of Columbia (4 trials); Greenville, North Carolina (4 trials); Iowa City, Iowa (3 trials) and 7 other cities.
Featured Idiopathic Thrombocytopenic Purpura Studies
Highlighted recruiting studies for idiopathic thrombocytopenic purpura, selected by enrollment size and research scope.
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with...
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than four prior treatments, and with no change in IC TPO-RA dose in at least the last 14 days prior to the start of ianaluma...
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed. The main aim of this study is to check how safe mezagitamab is and how well it is tolerated by adults with chronic primary ITP, if given over a longer time. Other aims are...
Frequently Asked Questions About Idiopathic Thrombocytopenic Purpura Clinical Trials
Are there idiopathic thrombocytopenic purpura clinical trials near me?
Yes, there are 11 idiopathic thrombocytopenic purpura clinical trials currently recruiting across 42+ cities in the United States, including Los Angeles, California; Boston, Massachusetts; Washington D.C., District of Columbia. Browse the studies above to find one at a location convenient for you.
How do I join a idiopathic thrombocytopenic purpura clinical trial?
To join a idiopathic thrombocytopenic purpura clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are idiopathic thrombocytopenic purpura clinical trials free?
Yes, participation in idiopathic thrombocytopenic purpura clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of idiopathic thrombocytopenic purpura treatments are being studied?
Current idiopathic thrombocytopenic purpura clinical trials are testing a range of approaches across PHASE3 (5 studies), PHASE2 (5 studies), PHASE1 (1 study). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 10 research organizations.
Is it safe to participate in idiopathic thrombocytopenic purpura clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 15, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 15, 2026 · Data from ClinicalTrials.gov